1006614-49-8

Usage

Uses

Used in Pharmaceutical Industry:
(1R trans)-2-(3,4-difluorophenyl)cyclopropane amine. HCl is used as a pharmaceutical intermediate for the synthesis of various drugs. The cyclopropane and difluorophenyl groups in its structure may provide unique binding properties and selectivity, making it a valuable component in the development of new medications.
Used in Organic Synthesis:
(1R trans)-2-(3,4-difluorophenyl)cyclopropane amine. HCl is used as a building block in organic synthesis. Its unique structure allows for the formation of various derivatives and analogs, which can be further utilized in the synthesis of complex organic molecules, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Medicinal Chemistry Research:
(1R trans)-2-(3,4-difluorophenyl)cyclopropane amine. HCl is used as a research tool in medicinal chemistry. Its unique structure and properties make it a promising candidate for studying the interactions between biological targets and potential drug molecules, aiding in the discovery of novel therapeutic agents.
Used in Drug Design and Optimization:
(1R trans)-2-(3,4-difluorophenyl)cyclopropane amine. HCl is used in the design and optimization of drug candidates. Its unique structural features can be leveraged to improve the potency, selectivity, and pharmacokinetic properties of new drugs, leading to the development of more effective and safer medications.

Upstream product

• 34036-07-2 3,4 difluorobenzaldehyde 
• 405-03-8 1-(3,4-difluorophenyl)ethene 
• 1006376-61-9 (1R,2R)-2-(3,4-difluorophenyl)-1-cyclopropanecarboxylic acid ethyl ester 
• 1353964-60-9 trans-(1R,2R)-2-(3,4-difluorophenyl)-N-hydroxycyclopropanecarboxamide 
• 1353964-63-2 trans-(1R,2R)-N-(acetyloxy)-2-(3,4-difluorophenyl)cyclopropane carboxamide 
• 1402222-66-5 trans-(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamine hydrochloride 
• 1459720-02-5 (1R,2S)-2-(3,4-difluorophenyl)cyclopropanoic acid methyl ester 
• 1459720-05-8 (1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarbohydrazide 
• 378236-67-0 (1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarbonyl azide 
• 1350749-64-2 tert-butyl ((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)carbamate 
• 898752-22-2 C₁₂H₁₂F₂O₃ 
• 1267369-02-7 isopropyl 4-(3,4-difluorophenyl)-4-oxobutanoate 
• 1248202-12-1 4-keto-4-(3,4-difluorophenyl)butyric acid methyl ester 

Downstream Products

• 274693-26-4 [3aR-[3aα,4α,6α,(1R,2S),6aα]]-2-[6-[[[7-(2-(3,4-difluorophenyl)cyclopropyl)]amino-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]tetrahydro-2,2-dimethyl-4H-cyclopenteno-1,3-dioxolan-4-yl]oxy]ethanol 
• 274693-27-5 ticagrelor 
• 1619240-45-7 (3aR,3bS,4aS,5R,5aS)-5-(6-(((1S,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-2-(phenylethynyl)-9H-purin-9-yl)-N,2,2-trimethyltetrahydrocyclopropa[3,4]cyclopenta [1,2-d][1,3]dioxole-3b(3aH)-carboxamide 
• 1619240-47-9 (3aR,3bS,4aS,5R,5aS)-5-(6-(((1S,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-2-(pyridin-2-ylethynyl)-9H-purin-9-yl)-N,2,2-trimethyltetrahydrocyclopropa[3,4]cyclopenta[1,2-d][1,3]dioxole-3b(3aH)-carboxamide 
• 1619240-20-8 (1S,2R,3S,4R,5S)-4-(6-(((1S,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-2-(phenylethynyl)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide 
• 376608-71-8 trans-(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamine (2R)-2-hydroxy-2-phenylacetic acid salt 
• 274693-25-3 methyl (((3aR,4S,6R,6aS)-6-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d](1,3)dioxol-4-yl)oxy)acetate 

Relevant academic research and scientific papers

Preparation method of phenyl-containing compound

The present invention discloses a method for preparing an phenyl-containing compound. The present invention provides a method for preparing a compound shown in formula I, comprising the following steps: in the presence of formamide or acetamide, in the pr

Preparation method of chiral aromatic cyclopropylamine and salt thereof and intermediate used in preparation method

The embodiment of the invention provides a preparation method of a compound as shown in a formula I or salt thereof, which comprises the following steps: (1) reacting a compound as shown in a formulaVI with a compound as shown in a formula VII in a first

Preparation method of ticagrelor chiral intermediate

The invention discloses a preparation method of a ticagrelor chiral intermediate. The ticagrelor chiral intermediate is trans-(1R, 2S)-2-(3, 4-difluorophenyl) cyclopropylamine. The method includes thesteps: taking cyclopropylamine as a raw material; perfo

Synthetic method for ticagrelor intermediate (1R,2S)-2-(3,4-difluorophenyl)cyclopropylamine

The invention discloses a synthetic method for a ticagrelor intermediate (1R,2S)-2-(3,4-difluorophenyl)cyclopropylamine. The method comprises the following steps: (5H)-furan-2-one is taken as a starting raw material, the (5H)-furan-2-one and a 3,4-difluor

A process for preparing (1 R, 2 S) - 2 - (3, 4 - difluorophenyl) amine method

The invention relates to a method for preparation of (1R,2S)-2-(3,4-difluorophenyl)cyclopropylamine represented by the formula I. The method adopts 1-(3,4-difluorophenyl)ethylene as a raw material, a dextro-laevo isomer of the formula I is obtained succes

Method for synthesizing (1R,2S)-1-amino-(3,4-difluorophenyl)-cyclopropane

The present invention relates to a method for synthesizing (1R,2S)-1-amino-(3,4-difluorophenyl)-cyclopropane. The method is characterized by comprising: 1) mixing 3,4-difluorobenzaldehyde and bis(pinacolato)diboron in tetrahydrofuran to obtain a mixture A

for standard auspicious Luo river intermediate preparation method

The inventiondiscloses a preparation method of ticagrelor. The method comprises the following steps: (1) reducing a compound shown in a formula III in the presence of a proton source provided by sodium borohydride or potassium borohydride and diethyl aniline hydrochloride to obtain a compound shown in a formula IV; (2) reacting the compound IV in the presence of alkali to generate a compound VI; (3) hydrolyzing the compound VI without purification to generate a compound VII; (4) reacting the compound VII to generate acyl chloride, reacting the acyl chloride to generate formamide, thus obtaining a compound shown in a formula IX; and (5) carrying out Hofmann rearrangement on the compound IX to obtain a compound shown in a formula II. Regents used in the method are nontoxic, harmless, environmentally friendly and low in price; the used key reagents can be recycled. Therefore, the method is applicable to industrial production.

(1 R, 2 S) - 2 - (3, 4 - difluorophenyl) amine ·D - mandelic acid salt preparation method

The invention discloses a preparation method of (1R,2S)-2-(3,4-difluorophenyl) rolicyprine.D-mandelate. The preparation method comprises the following steps: carrying out cyclopropanation on a compound shown in a formula V to obtain a compound shown in a formula IV; carrying out amide generation and Hofmann degradation to obtain a compound shown in a formula II; and performing salification with D-mandelic acid to obtain a compound shown in a formula I. The compound shown in the formula V is prepared in a way that a compound shown in a structure formula VI is subjected to CBS asymmetric reduction reaction, wherein a catalyst for the CBS asymmetric reduction reaction is a compound shown in a structural formula VII, and a reduction agent for the CBS asymmetric reduction reaction can be borane-tetrahydrofuran or borane-N,N-diethyl phenylamine.

Synthetic method of ticagrelor midbody

The invention provides a novel synthetic method of a ticagrelor midbody (1). The synthetic method comprises the following steps: enabling a compound (2) and a compound (3) to have asymmetric tertiary cyclization reaction under the catalysis of rhodium (a

Process for preparing aromatic hot melt adhesives and amine chemical method

The invention relates to a method for preparing trans-aryl cyclopropanecarbonitrile with a structure shown in a formula (IV) in the specification through reaction between aryl substituted ethylene oxide and cyan substituted phosphate and further relates t